(34.204.201.220) 您好!臺灣時間:2021/04/19 18:03
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:黃淳瑄
研究生(外文):Chun-Hsuan Huang
論文名稱:慢性 C 型肝炎患者接受長效型干擾素合併 Ribavirin 治療之健康相關生活品質之探討
論文名稱(外文):Health-related quality of life in chronic hepatitis C patients with pegylated interferon and ribavirin therapy
指導教授:楊美雪楊美雪引用關係
指導教授(外文):Mei-Hsueh Yang
口試委員:林森為許秉毅
口試日期:2014-07-10
學位類別:碩士
校院名稱:嘉南藥理大學
系所名稱:醫務管理系
學門:商業及管理學門
學類:醫管學類
論文種類:學術論文
論文出版年:2014
畢業學年度:102
語文別:中文
論文頁數:96
中文關鍵詞:慢性 C 型肝炎長效型干擾素Ribavirin健康相關生活品質
外文關鍵詞:chronic hepatitis Cpegylated interferonribavirinhealth- related quality of life
相關次數:
  • 被引用被引用:0
  • 點閱點閱:220
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:13
  • 收藏至我的研究室書目清單書目收藏:0
目的:長效型干擾素合併 Ribavirin 治療會使慢性 C 型肝炎 (chronic hepatitis C, CHC) 患者之健康相關生活品質 (health related quality of life, HRQL) 降低。本研究旨在探討不同治療階段的 CHC 患者 HRQL 之影響。研究方法:以橫斷式研究設計,採立意取樣方式選取南部某區域教學醫院 149 位符合全民健保加強 CHC 治療試辦計畫患者為對象。採用台灣簡明版世界衛生組織生活品質量表為研究工具。相關資料以描述性統計分析與單因子變異數分析。研究結果:治療前與治療結束後第 24 週的 CHC 患者之環境健康範疇顯著低於其他健康範疇,而治療期間之 CHC 患者的社會關係範疇顯著較其他健康範疇佳。治療前與治療結束後第 24 週之CHC 患者的生理健康範疇、心理健康範疇與整體健康相關生活品質之平均得分著顯著高於治療期間第 4 週與第 12 週者,但治療期間第 24 週的 CHC 患者之心理健康範疇比治療前者差,未顯著差異。治療結束後第 24 週的 CHC 患者之環境健康範疇顯著比治療期間第 24 週者佳。社會健康範疇並未因治療階段不同而有顯著差異。結論﹕CHC 患者在不同治療階段有不同的 HRQL 之影響,故了解治療對其不同階段的影響,助於臨床照護 CHC 患者的醫護人員參考。
Objectives: Combination therapy of pegylated interferon (PEG-IFN) and ribavirin (RBV) in chronic hepatitis C (CHC) is associated impaired health-related quality of life during therapy. The purpose of this study was to evaluate the patients' perceptions of health-related quality of life (HRQL) during different time periods of the therapy. Methods: Cross-sectional study of a purposive sample of patients recruited from a regional teaching hospital in southern Taiwan. A total of 149 patients with CHC who were enrolled in the Bureau of National Health Insurance (BNHI) demonstration project for enhancement of hepatitis C virus treatment had evaluation of HRQL using the short version of the world health organization quality of life (WHOQOL-BREF) questionnaire. Descriptive statistics were used to describe the basic features of the subjects in the study. One-way analysis of variance was applied to compare the differences of HRQL in the different periods during PEG-IFN and RBV combination therapy. Results: Patients with chronic hepatitis C at pretreatment and the 24-week after stopping PEG-IFN and RBV treatment had significantly lower HRQL on environmental health domain than other domains of the WHOQOL-BREF, while the score of social relationships domain at the time periods during PEG-IFN and RBV treatment was significantly higher HRQL than other domains’ score of the WHOQOL-BREF. Compared to the patients at the 4-week and 12-week periods of PEG-IFN and RBV treatment, patients at the pretreatment and 24-week after stopping treatments had significantly higher physical health, psychological health and global HRQL scores, however, at the 24-week periods in treatment of patients with chronic hepatitis C had lower psychological health domains scores than the pretreatment, but no significant differences. Patients with chronic hepatitis C at the 24-week after stopping PEG-IFN and RBV treatment had significantly higher HRQL on environmental health domain scores than the 24-week periods. There was no significant difference in social relationships HQRL over the entire treatment period of PEG-IFN and RBV treatment. Conclusions: For patients with CHC, PEG-IFN and RBV combination therapy related HRQL impairment could be inconsistent over the different time periods of treatment. The author hopes this study will provide references for nursing care patients with CHC.
中文摘要 Ⅰ
Abstract Ⅱ
誌謝 Ⅳ
目錄 Ⅴ
表目錄 Ⅷ
圖目錄 Ⅸ
第一章 緒論 1
第一節 研究背景與動機 1
第二節 研究目的 4
第三節 名詞界定 5
第二章 文獻探討 6
第一節 慢性C型肝炎疾病之流行病學 6
第二節 慢性C型肝炎之治療與治療反應之評估 10
第三節 慢性C型肝炎之治療健康相關生活品質 13
第三章 研究方法 40
第一節 研究設計 40
第二節 研究對象及資料收集 41
第三節 研究工具 43
第四節 研究變項與操作型定義 49
第五節 資料處理與分析 50
第四章 研究結果 51
第一節 研究對象基本特性分布 51
第二節 各治療階段不同健康範疇之差異 56
第三節 CHC患者不同治療階段之健康相關生活品質的變化 59
第四節 各健康相關生活品質範疇不同治療階段之差異 60
第五章 討論 64
第一節 長效型干擾素合併RBV治療之CHC患者健康相關生活品質
現況 64
第二節 長效型干擾素合併RBV治療之CHC患者各健康相關生活品
質不同治療階段之差異 66
第六章 結論與建議 71
第一節 結論 71
第二節 研究限制 71
第三節 建議 72
參考文獻 74
中文部分 74
英文部分 76
附錄 83
附錄一 同意臨床試驗證明書 83
附錄二 台灣版世界衛生組織生活品質問卷使用授權書 84


















參考資料
中文部分
台灣世界衛生組織研究中心(2011年07月28日).WHO相關訊息-全球
20億人感染肝炎病毒.取自 http://www.twwho.org/pub/news.asp?catid
=1744&ctxid=3302
吳珠枝、陳建和(2008).不同運動環境中身體健康效益之研究-以台北榮
總護理人員為例.醫護科技學刊,10(2),119-132。
林貴滿(2011).第十章消化系統疾病病人之護理.載於胡月娟總校閱,
內外科護理學上冊(頁712-720).台北:華杏。
林冠品、曾士婷、熊德筠、陳伯中、郭志宏(2008).疾病狀況、憂鬱與糖尿病個案生活品質之相關探討.弘光學報,53,83-94。
姚開屏(2005).台灣版世界衛生組織生活品質問卷之發展及使用手冊(第二版).台北:台灣版世界衛生組織品質問卷發展小組。
姚開屏(2002a).健康相關生活品質概念與測量原理之簡介.臺灣醫學,6(2),183-192。
姚開屏(2002b).台灣版世界衛生組織生活品質問卷之發展與應用.臺灣醫學,6(3),193-200。
陳妮婉、張彩秀、張淑萍、宋琇鈺(2011).護理人員健康促進生活型態與生活品質之關係探討.澄清醫護管理雜誌,7(2),27-37。
黃俐綾、宋琇鈺、劉麗芳、張彩秀(2010).慢性 C 型肝炎病患接受干擾
素與 Ribavirin 合併治療之症狀困擾、憂鬱與生活品質之探討.護理
暨健康照護研究,6(3),183-190。
葉淑琴、孫嘉玲、馬麗卿、林燕如、謝湘俐(2012).不同分期慢性腎臟疾病患者憂鬱狀態及健康相關生活品質之研究.台灣腎臟護理學會雜誌,11(3),16-32。
楊克平、尹祚芊(1999).癌末病患健康相關生活品質內涵之確認.護理研究,7(2),129-144。
衛生福利部統計處(2013年07月16日).民國101年死因統計年報.取自http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_
no=2747
盧瑞芬、曾旭民、蔡益堅(2002).國民生活品質評量(I):SF-36台灣版
的發展及心理計量特質分析.台灣衛誌,22(6),501-511。
羅淑芬、胡文郁(2008).癌症病人健康相關生活品質之概念與測量工具
之評析.安寧醫療雜誌,13(1),42-57。




英文部分
Amodio, P., Salari, L., Montagnese, S., Schiff, S., Neri, D., Bianco, T., et al. (2012). Hepatitis C virus infection and health-related quality of life. World journal of gastroenterology: WJG, 18(19), 2295.
Bowling, A. (Ed.). (1995). Measuring disease: a review of disease specific-
quality of life measurement scales. Philadelphia.: Open University
Press.
Chang, S. C., Ko, W. S., Wu, S. S., Peng, C. Y., & Yang, S. S. (2008). Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy. Journal of the Formosan Medical Association, 107(6), 454-462.
Chen, C. H., Yang, P. M., Huang, G. T., Lee, H. S., Sung, J. L., & Sheu, J. C. (2007). Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. Journal of the Formosan Medical Association, 106(2), 148-155.
Chen, S. L., & Morgan, T. R. (2006). The natural history of hepatitis C virus
(HCV) infection. International journal of medical sciences, 3(2), 47-52.
Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003). Defining clinically meaningful change in health-related quality of life. Journal of clinical epidemiology, 56(5), 395-407.
Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244(4902),
359-362.
Dan, A. A., Martin, L. M., Crone, C., Ong, J. P., Farmer, D. W., Wise, T., et al. (2006). Depression, anemia and health-related quality of life in chronic hepatitis C. Journal of hepatology, 44(3), 491-498.
Dusheiko, G. (1997). Side effects of α interferon in chronic hepatitis C. Hepat-
ology, 26(S3), 112S-121S.
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales Jr, F. L., et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347(13), 975-982.
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009). Diagnosis, management, and treatment of hepatitis C: an update. Hepatology, 49(4), 1335-1374.
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin,
P., et al. (2004). Peginterferon-α2a and ribavirin combination thera-
py in chronic hepatitis Ca randomized study of treatment duration
and ribavirin dose. Annals of internal medicine, 140(5), 346-355.
Hassanein, T., Cooksley, G., Sulkowski, M., Smith, C., Marinos, G., Lai, M.Y., et al. (2004). The impact of peginterferon alfa-2a plus ribavirin combinat-
ion therapy on health-related quality of life in chronic hepatitis C.
Journal of hepatology, 40(4), 675-681.
Kang, S. C., Hwang, S. J., Lee, S. H., Chang, F. Y., & Lee, S. D. (2005). Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World Journal of Gastroen-
terology, 11(47), 7494.
Kao, J. H., Chen, P. J., Lai, M. Y., Yang, P. M., Sheu, J. C., Wang, T. H., et al. (1995). Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. Journal of clinical gastroenterology, 21(3), 233-237.
Kerr, C., Lloyd, A., Ali, S., Gore, C., & Tyas, D. A. (2012). Impact of Treatment Attributes of Peginterferon for Hepatitis C on Quality of Life and Treatment Preference. Health Outcomes Research in Medicine, 3(3), e153-e167.
Lavanchy, D. (2008). Chronic viral hepatitis as a public health issue in the world. Best Practice & Research Clinical Gastroenterology, 22(6), 991-1008.
Lavanchy, D. (2011). Evolving epidemiology of hepatitis C virus. Clinical
Microbiology and Infection, 17(2), 107-115.
Lee, C. M., Lu, S. N., Hung, C. H., Tung, W. C., Wang, J. H., Tung, H. D., et al. (2006). Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical implications. Transactions of the Royal Society of Tropical Medicine and Hygiene, 100(8), 767-774.
Lee, S. D., Yu, M. L., Cheng, P. N., Lai, M. Y., Chao, Y. C., Hwang, S. J., et al. (2005). Comparison of a 6‐month course peginterferon α‐2b plus
ribavirin and interferon α‐2b plus ribavirin in treating Chinese
patients with chronic hepatitis C in Taiwan. Journal of viral hepatitis
, 12 (3), 283-291.
Liu, C. J., Chuang, W. L., Lee, C. M., Yu, M. L., Lu, S. N., Wu, S. S., et al. (2009). Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology,
136(2), 496-504.
Lu, S. N., Chue, P. Y., Chen, H. C., Wu, M. H., Chen, I. L., Huang, J. F., et al. (1997). Different viral aetiology of hepatocellular carcinoma between two
hepatitis B and C endemic townships in Taiwan. Journal of gastroenter-
ology and hepatology, 12(7), 547-550.
Maheshwari, A., Ray, S., & Thuluvath, P. J. (2008). Acute hepatitis C. The Lancet, 372(9635), 321-332.
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M.,
Reindollar, R., et al. (2001). Peginterferon alfa-2b plus ribavirin
compared with interferon alfa-2b plus ribavirin for initial treatment
of chronic hepatitis C: a randomised trial. The Lancet, 358(9286),
958-965.
Maylin, S., Michelle, M. P., Moucari, R., Boyer, N., Ripault, M. P., Dominique, C. H., et al. (2008). Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology, 135(3), 821-829.
Ni, Y. H., Chang, M. H., Huang, L. M., Chen, H. L., Hsu, H. Y., Chiu, T. Y., et al. (2001). Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Annals of internal medicine, 135(9), 796-800.
Omata, M., Kanda, T., Yu, M. L., Yokosuka, O., Lim, S. G., Jafri, W., et al. (2012). APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatology International, 6(2), 409-435.
Patrick, D. L., & Erickson, P. (1993). Assessing health-related quality of life for clinical decision-making Quality of life assessment: key issues in the 1990s (pp. 11-63): Springer.
Pojoga, C., Dumitraşcu, D., Pascu, O., & Grigorescu, M. (2006). The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The Romanian experience. Journal of gastrointestinal and liver diseases, 15(1), 31-35.
Purcell, R. (1997). The hepatitis C virus: overview. Hepatology, 26(S3), 11S-
14S.
Sinakos, E., Gigi, E., Lalla, T., Bellou, A., Sykja, A., & Orphanou, E. (2010). Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment. Hippokratia, 14(2), 122-125.
Skevington, S. M., Lotfy, M., & O'Connell, K. A. (2004). The World Health
Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Quality of life Research, 13(2), 299-310.
Sung, H., Chang, M., & Saab, S. (2011). Management of hepatitis C antiviral therapy adverse effects. Current Hepatitis Reports, 10(1), 33-40.
Testa, M. A., & Simonson, D. C. (1996). Assessment of quality-of-life out-
comes. New England Journal of Medicine, 334(13), 835-840.
Thein, H. H., Yi, Q., Dore, G. J., & Krahn, M. D. (2008). Estimation of stage-
specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology, 48(2), 418-431.
The WHOQOL Group (1998). The World Health Organization quality of life
assessment (WHOQOL): development and general psychometric
properties. Social science & medicine, 46(12), 1569-1585.
Tsai, M. C., Kee, K. M., Chen, Y. D., Lin, L. C., Tsai, L. S., Chen, H. H., et al.
(2007). Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV‐endemic areas in an HBV‐endemic country: Geographic variations among 502 villages in southern Taiwan. Journal of gastroenterology and hepatology, 22(1), 92-98.
Wang, J. T., Wang, T. H., Lin, J. T., Lee, C. Z., Sheu, J. C., & Chen, D. S.
(1995). Effect of hepatitis C antibody screening in blood donors on post-
transfusion hepatitis in Taiwan. Journal of gastroenterology and hepat-
ology, 10(4), 454-458.
Ware Jr, J. E., & Gandek, B. (1998). Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. Journal of
clinical epidemiology, 51(11), 903-912.
Ware Jr, J. E., & Sherbourne, C. D. (1992). The MOS 36-ltem short-form health survey (SF-36): I. Conceptual framework and item selection. Medical care, 30(6), 473-483.
WHO. Constitution of the World Health Organization as adopted by the Inter-
national Health Conference, New York 19–22 June, 1946; signed on 22 July 1946 by the representatives of 61 States (Official Records of the World Health Organization no 2).
Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-
related quality of life. JAMA: the journal of the American Medical
Association, 273(1), 59-65.
Yu, M. L., & Chuang, W. L. (2009). Treatment of chronic hepatitis C in Asia: when East meets West. Journal of gastroenterology and hepatology, 24
(3), 336-345.
Yu, M. L., Chuang, W. L., Chen, S. C., Dai, C. Y., Hou, C., Wang, J. H., et al. (2001). Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyper-
endemic areas and a tertiary referral center in Taiwan. Journal of
medical virology, 65(1), 58-65.
Yu, M. L., Dai, C. Y., Huang, J. F., Hou, N. J., Lee, L. P., Hsieh, M. Y., et al. (2007). A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut, 56(4), 553-559.
Yu, M. L., Dai, C. Y., Lin, Z. Y., Lee, L. P., Hou, N. J., Hsieh, M. Y., et al.
(2006). A randomized trial of 24‐vs. 48‐week courses of PEG inter-
feron α‐2b plus ribavirin for genotype‐1b‐infected chronic hepatitis
C patients: a pilot study in Taiwan. Liver International, 26(1), 73-81.
Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., et al. (2000). Peginterferon alfa-2a in patients with chronic hepatitis C. New England Journal of Medicine, 343(23), 1666-1672.








QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔